Ovarian Cancer Clinical Trial Breakthroughs and Impact on Management

被引：12

作者：

Previs, Rebecca Ann ^{[1
]}

Secord, Angeles Alvarez ^{[1
]}

机构：

[1] Duke Univ, Duke Canc Inst, Dept Obstet & Gynecol, Div Gynecol Oncol,Med Ctr, Box 3079, Durham, NC 27710 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2019年 / 46卷 / 01期

关键词：

Ovarian cancer; Clinical trials; Cytoreduction; PARP inhibitor; Bevacizumab; Immunotherapy; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; PRIMARY PERITONEAL CANCER; PACLITAXEL PLUS CARBOPLATIN; PHASE-III TRIAL; OPEN-LABEL; DOUBLE-BLIND; NEOADJUVANT CHEMOTHERAPY; FALLOPIAN-TUBE; 1ST-LINE CHEMOTHERAPY;

D O I：

10.1016/j.ogc.2018.09.005

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance therapy. Maintenance therapy has been shown to enhance progression-free survival. Recent surgical trials have evaluated the role of neoadjuvant chemotherapy versus primary debulking at the time of diagnosis in advanced stage ovarian cancer. The role of lymph node dissection and secondary cytoreductive surgeries have also been evaluated. This article reviews contemporary trials of maintenance therapy and novel drug development.

引用

页码：67 / +

页数：23

共 50 条

[41] Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management
Masaki Mandai
Ken Yamaguchi
Noriomi Matsumura
Tsukasa Baba
Ikuo Konishi
International Journal of Clinical Oncology, 2009, 14 : 383 - 391
[42] Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations
Ferrandina, Gabriella
Legge, Francesco
Salutari, Vanda
Paglia, Amelia
Testa, Antonia
Scambia, Giovanni
EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) : 2296 - 2302
[43] Clinical utility of targeted treatments in the management of epithelial ovarian cancer
Twu, Cheryl
Han, Ernest S.
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 233 - 244
[44] Cachexia and bladder cancer: clinical impact and management
Lokeshwar, Soum D.
Press, Benjamin H.
Nie, James
Klaassen, Zachary
Kenney, Patrick A.
Leapman, Michael S.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2021, 15 (04) : 260 - 265
[45] Interim results of OvaRex clinical trial demonstrate clinical benefit in ovarian cancer patients
不详
ONCOLOGY-NEW YORK, 2001, 15 (08): : 983 - 983
[46] The Global Impact of the Gynecologic Cancer InterGroup in Enhancing Clinical Trials in Ovarian Cancer
Bacon, Monica
Kitchener, Henry
Stuart, Gavin C. E.
Vermorken, Jan B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (04) : 746 - 749
[47] CLINICAL TRIAL PARTICIPATION AND OUTCOMES IN OVARIAN CANCER: A CASE CONTROL STUDY
Horsley, L. H.
Booth, S.
Potter, P.
Clamp, A.
Jayson, G. C.
Hasan, J.
ANNALS OF ONCOLOGY, 2014, 25
[48] Factors influencing clinical trial enrollment among ovarian cancer patients
Greenwade, Molly M.
Moore, Kathleen N.
Gillen, Jessica M.
Ding, Kai
Rowland, Michelle R.
Crim, Aleia K.
Kleis, Bailey
Gunderson, Camille C.
GYNECOLOGIC ONCOLOGY, 2017, 146 (03) : 465 - 469
[49] Clinical Trial Participation Is Associated With Improved Outcome in Women With Ovarian Cancer
Robinson, William R.
Ritter, Joyce
Rogers, April S.
Tedjarati, Sean
Lieberenz, Christy
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (01) : 124 - 128
[50] ESTIMATING CROSSOVER BIAS IN A RANDOMIZED CLINICAL TRIAL OF OVARIAN CANCER TREATMENT
Kuehne, F.
Rochau, U.
Paracha, N.
Sabate, E.
Siebert, U.
VALUE IN HEALTH, 2014, 17 (07) : A564 - A564

← 1 2 3 4 5 →